Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with a number of representatives of the Egyptian Chamber of Pharmaceutical Industry, headed by Dr. Gamal El-Laithy, Chairman of the Chamber, to discuss the decision on renewing the technical requirements for pharmaceutical factories. This meeting comes within the framework of the Authority’s ongoing efforts to develop the regulatory system and enhance levels of quality and safety in the pharmaceutical manufacturing sector.
The decision aims to reinforce sustained compliance with Good Manufacturing Practices (GMP) and approved regulatory standards, contributing to improved institutional performance of factories, strengthened regulatory compliance, and ensuring the highest levels of quality, efficacy, and safety of pharmaceutical products circulating in the Egyptian market.
Dr. Ali El-Ghamrawy affirmed that the Egyptian Drug Authority places great importance on strengthening partnerships with the industrial sector and continuously developing regulatory policies and procedures in line with global developments. This approach supports the sustainability of the national pharmaceutical industry. He stressed that the application of the highest standards of quality and governance represents a fundamental pillar in ensuring the safety and effectiveness of medicines and protecting public health.
The Egyptian Drug Authority also emphasized that the decision is aligned with international best practices and standards, enhances the competitiveness of the national pharmaceutical industry, and encourages investment in upgrading manufacturing infrastructure and advancing technical and technological capabilities.
Representatives of the Egyptian Chamber of Pharmaceutical Industry expressed their appreciation for the efforts of the Egyptian Drug Authority in developing the regulatory and oversight framework, as well as its continuous commitment to supporting the national industry and addressing the challenges faced by manufacturers. They confirmed that the Authority’s regulatory decisions contribute to market stability, improve product quality, and enhance the competitiveness of Egyptian medicines locally, regionally, and internationally.
The Authority concluded by reaffirming that the primary objective of this decision is to protect citizens’ health and ensure the availability of safe, effective, and high-quality medicines, thereby strengthening confidence in the national pharmaceutical system.